Industry
Biotechnology
Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. Janux Therapeutics, Inc. is also developing a Tumor Activated Immunomodulator (TRACIr) costimulatory bispecific product candidate against programmed death-ligand 1 and CD28 designed to improve the anti-tumor activity of T cells. In addition, its EGFR-TRACTr is designed to target EGFR in many cancer types with multiple approved monoclonal antibodies. The company was incorporated in 2017 and is headquartered in La Jolla, California.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Benzinga Newsdesk
August 19, 2024 | 11:41 am
Portfolio Pulse from Benzinga Insights
August 09, 2024 | 9:00 pm
Portfolio Pulse from Benzinga Newsdesk
August 09, 2024 | 8:30 pm
Portfolio Pulse from Benzinga Newsdesk
August 08, 2024 | 2:48 pm
Portfolio Pulse from Benzinga Newsdesk
August 08, 2024 | 1:28 pm
Portfolio Pulse from Benzinga Newsdesk
August 07, 2024 | 8:05 pm
Portfolio Pulse from Benzinga Newsdesk
July 22, 2024 | 8:02 pm
Portfolio Pulse from Michael Juliano
July 18, 2024 | 5:36 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.